Key facts
- Positrigo’s last known valuation is $25.9M (Oct 2025).
- It has raised $26.3M; the latest was Later Stage VC ($10.0M) in Oct 2025.
- Notable investors include European Innovation Council, Venture Kick, European Commission, Innosuisse, Zürcher Kantonalbank — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Positrigo
- ·The full record, as it builds
Funding rounds
No funding rounds for Positrigo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Positrigo
Developer of brain positron emission tomography systems intended to make functional imaging accessible and available for patients. The company offers a brain scanner for diagnostics, treatment monitoring, and the development of new therapies that help in treating specific medical conditions such as Lewy body dementia, Alzheimer's, vascular dementia, and frontotemporal dementia, enabling doctors to diagnose neurodegenerative diseases early in an affordable way.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2018
- Employees
- 23
- Website
- positrigo.com/
- Ownership
- Privately Held (backing)
Positrigo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Positrigo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Positrigo in its N-PORT filings yet. We sweep new filings monthly.